SeaStar Medical Boosts Revenue 69% on Pediatric AKI Expansion, Eyes Adult Market
Event summary
- SeaStar Medical reported a 69% year-over-year revenue increase to $0.5 million in Q1 2026, driven by adding 7 top-rated children’s hospitals to its QUELIMMUNE customer base.
- The company advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial for adult AKI patients, with 198 of 339 patients enrolled to date.
- SeaStar Medical initiated efforts for a modular post-marketing application (PMA) submission to expedite FDA approval for the adult AKI indication.
- The company anticipates achieving $2 million in net product revenue in 2026 and broadening QUELIMMUNE adoption to 15 additional top-ranked children’s medical centers.
The big picture
SeaStar Medical's strategic focus on expanding its QUELIMMUNE therapy into the adult AKI market represents a significant growth opportunity, given the adult market's 50x larger size compared to the pediatric market. The company's efforts to expedite regulatory approval through modular PMA submissions and its Breakthrough Device Designation from the FDA highlight its commitment to addressing critical unmet needs in the treatment of acute kidney injury. The broader applicability of the SCD therapy to other hyperinflammatory conditions positions SeaStar Medical at the forefront of innovative treatments for critically ill patients.
What we're watching
- Market Expansion
- The pace at which SeaStar Medical can expand its QUELIMMUNE customer base beyond the pediatric market into the significantly larger adult AKI market.
- Regulatory Approval
- Whether the modular PMA submission strategy will expedite FDA approval for the adult AKI indication, potentially accelerating commercialization.
- Execution Risk
- How SeaStar Medical will manage its cash position, which decreased from $12.0 million to $9.3 million, while advancing multiple clinical trials and commercial initiatives.
Related topics